{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T13:07:58Z","timestamp":1783688878912,"version":"3.55.0"},"reference-count":38,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2023,7,30]],"date-time":"2023-07-30T00:00:00Z","timestamp":1690675200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Human fibrinogen concentrate (Fibryga) received temporary approval for fibrinogen replacement therapy in France (2017), with subsequent full approval for congenital and acquired hypofibrinogenemia. We evaluated real\u2010world use for on\u2010demand treatment of bleeding and prophylaxis to enhance our knowledge on fibrinogen concentrate as an option for fibrinogen replacement. Data were retrospectively collected from adult and pediatric patients with fibrinogen deficiency. The primary end point was indication for fibrinogen concentrate use; the secondary end point was treatment success for on\u2010demand treatment\/perioperative prophylaxis. The study included 150 adult (median age, 62\u00a0years; range, 18\u201094\u00a0years) and 50 pediatric (median age, 3\u00a0years; range, 0.01\u201017\u00a0years) patients with acquired fibrinogen deficiency. Fibrinogen concentrate was administered to 47.3% for nonsurgical bleeding, 22.7% for surgical bleeding, and 30.0% for perioperative prophylaxis in adult patients, and to 4.0% for surgical bleeding and 96.0% for perioperative prophylaxis in pediatric patients. Cardiac surgeries accounted for 79.5%\/75.0% perioperative prophylaxis and 82.4%\/100.0% surgical bleeding cases in adult\/pediatric patients, respectively. The mean\u00a0\u00b1\u00a0standard deviation (SD, median) total fibrinogen doses were 3.06\u00a0\u00b1\u00a01.69\u00a0g (32.61\u00a0mg\/kg), 2.09\u00a0\u00b1\u00a01.36\u00a0g (22.99\u00a0mg\/kg), and 2.36\u00a0\u00b1\u00a01.25\u00a0g (29.67\u00a0mg\/kg) for adult nonsurgical bleeding, surgical bleeding, and perioperative prophylaxis, respectively; doses of 0.75\u00a0\u00b1\u00a00.35\u00a0g (47.64\u00a0mg\/kg) and 0.83\u00a0\u00b1\u00a00.62\u00a0g (55.56\u00a0mg\/kg) were used for pediatric surgical bleeding and perioperative prophylaxis, respectively. Treatment success was 85.7%\/97.1\/93.3% in adults and 50.0%\/87.5% in pediatrics for nonsurgical bleeding (adults only), surgical bleeding, and perioperative prophylaxis, respectively. Fibrinogen concentrate demonstrated favorable effectiveness and safety across the age groups. This study contributes to evidence supporting fibrinogen concentrate for bleeding control\/prevention in real\u2010world clinical practice, particularly for patients with acquired fibrinogen deficiency.<\/jats:p>","DOI":"10.1002\/jcph.2291","type":"journal-article","created":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T10:23:42Z","timestamp":1686306222000},"page":"1186-1196","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real\u2010World Experience with a Human Fibrinogen Concentrate: Clinical Data from Adult and Pediatric Patients Requiring Fibrinogen for Bleeding Control and Prevention"],"prefix":"10.1002","volume":"63","author":[{"given":"Francois","family":"St\u00e9phan","sequence":"first","affiliation":[{"name":"Service de R\u00e9animation Adultes H\u00f4pital Marie Lannelongue Groupe Hospitalier Paris Saint Joseph Le Plessis Robinson France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loriane","family":"Gutermann","sequence":"additional","affiliation":[{"name":"Service Pharmacie et St\u00e9rilisation H\u00f4pital Marie Lannelongue Groupe Hospitalier Paris Saint Joseph Le Plessis Robinson France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Bourget","sequence":"additional","affiliation":[{"name":"Service Pharmacie Centre Hospitalier de Valence Valence France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Djabarouti","sequence":"additional","affiliation":[{"name":"Service Pharmacie Groupe Hospitalier Sud CHU de Bordeaux Pessac France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Berdugo","sequence":"additional","affiliation":[{"name":"Service Pharmacie H\u00f4pital Saint\u2010Joseph Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yann","family":"Fardini","sequence":"additional","affiliation":[{"name":"Soladis Clinical Studies Roubaix France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Clerson","sequence":"additional","affiliation":[{"name":"Soladis Clinical Studies Roubaix France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"H\u00e9bert","sequence":"additional","affiliation":[{"name":"Service Pharmacie et St\u00e9rilisation H\u00f4pital Marie Lannelongue Groupe Hospitalier Paris Saint Joseph Le Plessis Robinson France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chafk\u00e9","family":"Belmokhtar","sequence":"additional","affiliation":[{"name":"Octapharma France SAS Boulogne\u2010Billancourt France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,7,30]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.117.308564"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/icvts\/ivy132"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.02297.x"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/TA.0b013e318160a57b"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01681.x"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0035-1564841"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/ACO.0000000000000176"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1213\/ANE.0b013e31822e1853"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-019-2347-3"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/ACO.0b013e32835afd28"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.17312"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08208.x"},{"key":"e_1_2_11_14_1","volume-title":"Administrative and Clinical Standards for Patient Blood Management Programs","author":"Society for the Advancement of patient Blood Management"},{"issue":"1","key":"e_1_2_11_15_1","first-page":"23","article-title":"Fibrinogen replacement therapy: a critical review of the literature","volume":"10","author":"Franchini M","year":"2012","journal-title":"Blood Transfus"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2009.03.001"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/aeu158"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15167"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2018.1458610"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/EJA.0000000000000630"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1309\/AJCPH16YXJEFSHEO"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/jog.13788"},{"issue":"3","key":"e_1_2_11_23_1","first-page":"171","article-title":"Targeted fibrinogen concentrate use in severe traumatic haemorrhage","volume":"21","author":"Seebold JA","year":"2019","journal-title":"Crit Care Resusc"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.jvca.2017.06.026"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biologicals.2017.12.003"},{"key":"e_1_2_11_26_1","volume-title":"Use of Fibryga, a Fibrinogen Concentrate in Real World: Retrospective Collection of Clinical Data","author":"U.S. National Library of Medicine. ClinicalTrials.gov"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01204.x"},{"key":"e_1_2_11_28_1","unstructured":"Electronic Medicines Compendium.Fibryga 1 g powder and solvent for solution for injection\/infusion. Summary of product characteristics. Accessed October 20 2022.https:\/\/www.medicines.org.uk\/emc\/product\/10315\/smpc"},{"key":"e_1_2_11_29_1","first-page":"1","article-title":"Variations and obstacles in the use of coagulation factor concentrates for major trauma bleeding across Europe: outcomes from a European expert meeting","author":"\u010cern\u00fd V","year":"2021","journal-title":"Eur J Trauma Emerg Surg"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14147"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/1471-0528.16699"},{"key":"e_1_2_11_32_1","unstructured":"Electronic Medicines Compendium. FibCLOT 1.5 g. Powder and solvent for solution for injection\/infusion. Accessed October 20 2022.https:\/\/www.medicines.org.uk\/emc\/medicine\/32987"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13174"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14665"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14727"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14230"},{"key":"e_1_2_11_37_1","unstructured":"Electronic Medicines Compendium.Riastap 1 g Powder for solution for injection\/infusion. Accessed July 26 2022.https:\/\/www.medicines.org.uk\/emc\/product\/5909\/smpc"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14392"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0039-3402759"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.2291","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T07:30:51Z","timestamp":1697182251000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/jcph.2291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,30]]},"references-count":38,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["10.1002\/jcph.2291"],"URL":"https:\/\/doi.org\/10.1002\/jcph.2291","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,30]]},"assertion":[{"value":"2023-01-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}